

Global Common Cancer-associated Antigens (CAAs) Vaccine Market Research Report 2023

<https://marketpublishers.com/r/G38322B9A3DAEN.html>

Date: December 2023

Pages: 88

Price: US\$ 2,900.00 (Single User License)

ID: G38322B9A3DAEN

Abstracts

Perhaps a more cost-effective option lies in developing vaccines using common cancer-associated antigens (CAAs), which in theory could treat a large number of tumours.

According to QYResearch's new survey, global Common Cancer-associated Antigens (CAAs) Vaccine market is projected to reach US\$ 724.9 million in 2029, increasing from US\$ 483 million in 2022, with the CAGR of 6.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Common Cancer-associated Antigens (CAAs) Vaccine market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Common Cancer-associated Antigens (CAAs) Vaccine market with multiple angles, which provides sufficient supports to readers' strategy and decision making.

By Company

Seattle Genetics

Merck Serono

Merck KGaA

GlaxoSmithKline

KAEL-GemVax

SELLAS Life Sciences

Celldex

Immatics Biotechnologies

Segment by Type

Tecemotide

Astuprotimut-R

Tertomotide

Nelipepimut-S

Others

Segment by Application

Pediatrics

Adults

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The Common Cancer-associated Antigens (CAAs) Vaccine report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies' Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies' Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size
Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Tecemotide

1.2.3 Astuprotimut-R

1.2.4 Tertomotide

1.2.5 Nelipepimut-S

1.2.6 Others

1.3 Market by Application

1.3.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Growth by
Application: 2018 VS 2022 VS 2029

1.3.2 Pediatrics

1.3.3 Adults

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Perspective
(2018-2029)

2.2 Common Cancer-associated Antigens (CAAs) Vaccine Growth Trends by Region

2.2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by
Region: 2018 VS 2022 VS 2029

2.2.2 Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by
Region (2018-2023)

2.2.3 Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size
by Region (2024-2029)

2.3 Common Cancer-associated Antigens (CAAs) Vaccine Market Dynamics

2.3.1 Common Cancer-associated Antigens (CAAs) Vaccine Industry Trends

2.3.2 Common Cancer-associated Antigens (CAAs) Vaccine Market Drivers

2.3.3 Common Cancer-associated Antigens (CAAs) Vaccine Market Challenges

2.3.4 Common Cancer-associated Antigens (CAAs) Vaccine Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Common Cancer-associated Antigens (CAAs) Vaccine Players by Revenue

3.1.1 Global Top Common Cancer-associated Antigens (CAAs) Vaccine Players by Revenue (2018-2023)

3.1.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Players (2018-2023)

3.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Common Cancer-associated Antigens (CAAs) Vaccine Revenue

3.4 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Concentration Ratio

3.4.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Common Cancer-associated Antigens (CAAs) Vaccine Revenue in 2022

3.5 Common Cancer-associated Antigens (CAAs) Vaccine Key Players Head office and Area Served

3.6 Key Players Common Cancer-associated Antigens (CAAs) Vaccine Product Solution and Service

3.7 Date of Enter into Common Cancer-associated Antigens (CAAs) Vaccine Market

3.8 Mergers & Acquisitions, Expansion Plans

4 COMMON CANCER-ASSOCIATED ANTIGENS (CAAS) VACCINE BREAKDOWN DATA BY TYPE

4.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by Type (2018-2023)

4.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Type (2024-2029)

5 COMMON CANCER-ASSOCIATED ANTIGENS (CAAS) VACCINE BREAKDOWN DATA BY APPLICATION

5.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by Application (2018-2023)

5.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market

Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2018-2029)

6.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2023)

6.4 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7 EUROPE

7.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2018-2029)

7.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2023)

7.4 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 ASIA-PACIFIC

8.1 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2018-2029)

8.2 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by

Region (2018-2023)

8.4 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 LATIN AMERICA

9.1 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2018-2029)

9.2 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2023)

9.4 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2018-2029)

10.2 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2023)

10.4 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 KEY PLAYERS PROFILES

11.1 Seattle Genetics

11.1.1 Seattle Genetics Company Detail

11.1.2 Seattle Genetics Business Overview

11.1.3 Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine

Introduction

11.1.4 Seattle Genetics Revenue in Common Cancer-associated Antigens (CAAs)

Vaccine Business (2018-2023)

11.1.5 Seattle Genetics Recent Development

11.2 Merck Serono

11.2.1 Merck Serono Company Detail

11.2.2 Merck Serono Business Overview

11.2.3 Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine

Introduction

11.2.4 Merck Serono Revenue in Common Cancer-associated Antigens (CAAs)

Vaccine Business (2018-2023)

11.2.5 Merck Serono Recent Development

11.3 Merck KGaA

11.3.1 Merck KGaA Company Detail

11.3.2 Merck KGaA Business Overview

11.3.3 Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine

Introduction

11.3.4 Merck KGaA Revenue in Common Cancer-associated Antigens (CAAs)

Vaccine Business (2018-2023)

11.3.5 Merck KGaA Recent Development

11.4 GlaxoSmithKline

11.4.1 GlaxoSmithKline Company Detail

11.4.2 GlaxoSmithKline Business Overview

11.4.3 GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine

Introduction

11.4.4 GlaxoSmithKline Revenue in Common Cancer-associated Antigens (CAAs)

Vaccine Business (2018-2023)

11.4.5 GlaxoSmithKline Recent Development

11.5 KAEL-GemVax

11.5.1 KAEL-GemVax Company Detail

11.5.2 KAEL-GemVax Business Overview

11.5.3 KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine

Introduction

11.5.4 KAEL-GemVax Revenue in Common Cancer-associated Antigens (CAAs)

Vaccine Business (2018-2023)

11.5.5 KAEL-GemVax Recent Development

11.6 SELLAS Life Sciences

11.6.1 SELLAS Life Sciences Company Detail

11.6.2 SELLAS Life Sciences Business Overview

11.6.3 SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Introduction

11.6.4 SELLAS Life Sciences Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

11.6.5 SELLAS Life Sciences Recent Development

11.7 Celldex

11.7.1 Celldex Company Detail

11.7.2 Celldex Business Overview

11.7.3 Celldex Common Cancer-associated Antigens (CAAs) Vaccine Introduction

11.7.4 Celldex Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

11.7.5 Celldex Recent Development

11.8 Immatics Biotechnologies

11.8.1 Immatics Biotechnologies Company Detail

11.8.2 Immatics Biotechnologies Business Overview

11.8.3 Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Introduction

11.8.4 Immatics Biotechnologies Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

11.8.5 Immatics Biotechnologies Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029

Table 2. Key Players of Tecemotide

Table 3. Key Players of Astuprotimut-R

Table 4. Key Players of Tertomotide

Table 5. Key Players of Nelipepimut-S

Table 6. Key Players of Others

Table 7. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029

Table 8. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 9. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2018-2023) & (US\$ Million)

Table 10. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Region (2018-2023)

Table 11. Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 12. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Region (2024-2029)

Table 13. Common Cancer-associated Antigens (CAAs) Vaccine Market Trends

Table 14. Common Cancer-associated Antigens (CAAs) Vaccine Market Drivers

Table 15. Common Cancer-associated Antigens (CAAs) Vaccine Market Challenges

Table 16. Common Cancer-associated Antigens (CAAs) Vaccine Market Restraints

Table 17. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue by Players (2018-2023) & (US\$ Million)

Table 18. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Players (2018-2023)

Table 19. Global Top Common Cancer-associated Antigens (CAAs) Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Common Cancer-associated Antigens (CAAs) Vaccine as of 2022)

Table 20. Ranking of Global Top Common Cancer-associated Antigens (CAAs) Vaccine Companies by Revenue (US\$ Million) in 2022

Table 21. Global 5 Largest Players Market Share by Common Cancer-associated Antigens (CAAs) Vaccine Revenue (CR5 and HHI) & (2018-2023)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Common Cancer-associated Antigens (CAAs) Vaccine Product Solution and Service

Table 24. Date of Enter into Common Cancer-associated Antigens (CAAs) Vaccine Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2018-2023) & (US\$ Million)

Table 27. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Type (2018-2023)

Table 28. Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 29. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Type (2024-2029)

Table 30. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2018-2023) & (US\$ Million)

Table 31. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Application (2018-2023)

Table 32. Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 33. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Application (2024-2029)

Table 34. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 35. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2023) & (US\$ Million)

Table 36. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2024-2029) & (US\$ Million)

Table 37. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 38. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2023) & (US\$ Million)

Table 39. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2024-2029) & (US\$ Million)

Table 40. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 41. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2018-2023) & (US\$ Million)

Table 42. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2024-2029) & (US\$ Million)

Table 43. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 44. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2023) & (US\$ Million)

Table 45. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2024-2029) & (US\$ Million)

Table 46. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 47. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2023) & (US\$ Million)

Table 48. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2024-2029) & (US\$ Million)

Table 49. Seattle Genetics Company Detail

Table 50. Seattle Genetics Business Overview

Table 51. Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Product

Table 52. Seattle Genetics Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023) & (US\$ Million)

Table 53. Seattle Genetics Recent Development

Table 54. Merck Serono Company Detail

Table 55. Merck Serono Business Overview

Table 56. Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Product

Table 57. Merck Serono Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023) & (US\$ Million)

Table 58. Merck Serono Recent Development

Table 59. Merck KGaA Company Detail

Table 60. Merck KGaA Business Overview

Table 61. Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Product

Table 62. Merck KGaA Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023) & (US\$ Million)

Table 63. Merck KGaA Recent Development

Table 64. GlaxoSmithKline Company Detail

Table 65. GlaxoSmithKline Business Overview

Table 66. GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Product

Table 67. GlaxoSmithKline Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023) & (US\$ Million)

Table 68. GlaxoSmithKline Recent Development

Table 69. KAEL-GemVax Company Detail

Table 70. KAEL-GemVax Business Overview

Table 71. KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Product

Table 72. KAEL-GemVax Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023) & (US\$ Million)

Table 73. KAEL-GemVax Recent Development

Table 74. SELLAS Life Sciences Company Detail

Table 75. SELLAS Life Sciences Business Overview

Table 76. SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Product

Table 77. SELLAS Life Sciences Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023) & (US\$ Million)

Table 78. SELLAS Life Sciences Recent Development

Table 79. Celldex Company Detail

Table 80. Celldex Business Overview

Table 81. Celldex Common Cancer-associated Antigens (CAAs) Vaccine Product

Table 82. Celldex Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023) & (US\$ Million)

Table 83. Celldex Recent Development

Table 84. Immatics Biotechnologies Company Detail

Table 85. Immatics Biotechnologies Business Overview

Table 86. Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Product

Table 87. Immatics Biotechnologies Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023) & (US\$ Million)

Table 88. Immatics Biotechnologies Recent Development

Table 89. Research Programs/Design for This Report

Table 90. Key Data Information from Secondary Sources

Table 91. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 2. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type: 2022 VS 2029

Figure 3. Tecemotide Features

Figure 4. Astuprotimut-R Features

Figure 5. Tertomotide Features

Figure 6. Neli pepimut-S Features

Figure 7. Others Features

Figure 8. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Comparison by Application (2023-2029) & (US\$ Million)

Figure 9. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application: 2022 VS 2029

Figure 10. Pediatrics Case Studies

Figure 11. Adults Case Studies

Figure 12. Common Cancer-associated Antigens (CAAs) Vaccine Report Years Considered

Figure 13. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 14. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 15. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Region: 2022 VS 2029

Figure 16. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Players in 2022

Figure 17. Global Top Common Cancer-associated Antigens (CAAs) Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Common Cancer-associated Antigens (CAAs) Vaccine as of 2022)

Figure 18. The Top 10 and 5 Players Market Share by Common Cancer-associated Antigens (CAAs) Vaccine Revenue in 2022

Figure 19. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 20. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Country (2018-2029)

Figure 21. United States Common Cancer-associated Antigens (CAAs) Vaccine Market

Size YoY Growth (2018-2029) & (US\$ Million)

Figure 22. Canada Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 23. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Country (2018-2029)

Figure 25. Germany Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. France Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. U.K. Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. Italy Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Russia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Nordic Countries Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Region (2018-2029)

Figure 33. China Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. Japan Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. South Korea Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. Southeast Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. India Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. Australia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 40. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Country (2018-2029)

Figure 41. Mexico Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 42. Brazil Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 43. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 44. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Country (2018-2029)

Figure 45. Turkey Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 46. Saudi Arabia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 47. Seattle Genetics Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

Figure 48. Merck Serono Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

Figure 49. Merck KGaA Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

Figure 50. GlaxoSmithKline Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

Figure 51. KAEV-GemVax Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

Figure 52. SELLAS Life Sciences Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

Figure 53. Celldex Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

Figure 54. Immatics Biotechnologies Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

Figure 57. Key Executives Interviewed

I would like to order

Product name: Global Common Cancer-associated Antigens (CAAs) Vaccine Market Research Report 2023

Product link: <https://marketpublishers.com/r/G38322B9A3DAEN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G38322B9A3DAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

